Journal
JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK
Volume 15, Issue 3, Pages 411-419Publisher
HARBORSIDE PRESS
DOI: 10.6004/jnccn.2017.0038
Keywords
-
Categories
Funding
- NCI NIH HHS [R01 CA184843, R01 CA172670, K12 CA120780] Funding Source: Medline
Ask authors/readers for more resources
Although clinical management of colon cancer generally has not accounted for the primary tumor site, left-sided and right-sided colon cancers harbor different clinical and biologic characteristics. Right-sided colon cancers are more likely to have genome-wide hypermethylation via the CpG island methylator phenotype (CIMP), hypermutated state via microsatellite instability, and BRAF mutation. There are also differential exposures to potential carcinogenic toxins and microbiota in the right and left colon. Gene expression analyses further shed light on distinct biologic subtypes of colorectal cancers (CRCs), with 4 consensus molecular subtypes (CMSs) identified. Importantly, these subtypes are differentially distributed between right-and left-sided CRCs, with greater proportions of the microsatellite unstable/immune CMS1 and the metabolic CMS3 subtypes found in right-sided colon cancers. This review summarizes important biologic distinctions between right-and left-sided CRCs that likely impact prognosis and may predict for differential responses to biologic therapy. Given the inferior prognosis of stage III-IV right-sided CRCs and emerging data suggesting that anti-epidermal growth factor receptor antibody therapy is associated with worse survival in right-sided stage IV CRCs compared with left-sided cancers, these biologic differences between right-and left-sided CRCs provide critical context and may provide opportunities to personalize therapy.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available